Samadi Roghaieh, Shafiei Babak, Azizi Fereidoun, Ghasemi Asghar
Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Nuclear Medicine, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Cell J. 2017 Jul-Sep;19(2):184-193. doi: 10.22074/cellj.2016.4251. Epub 2017 Feb 22.
Radioactive iodine therapy is commonly used as an adjuvant therapy in follicular and papillary thyroid carcinoma (PTC) and in the treatment of Graves' disease (GD). The basis of this therapy is the accumulation of radioactive iodine by the sodium-iodide symporter (NIS) in the thyroid gland. Expression of NIS by extrathyroidal tissues such as islets of pancreas has been reported. Radioactive iodine uptake by pancreatic beta-cells can potentially damage these cells. In this study, we discuss the possible associations between radioactive iodine and glucose intolerance. Overall, radioactive iodine uptake by the pancreas may damage beta-cells and predispose patients to glucose intolerance or type 2 diabetes, particularly in patients exposed to radioactive iodine therapy following total thyroidectomy. Further studies are needed to clarify and confirm this association.
放射性碘疗法通常用作滤泡状和乳头状甲状腺癌(PTC)的辅助治疗以及格雷夫斯病(GD)的治疗。该疗法的基础是甲状腺中的钠-碘同向转运体(NIS)积累放射性碘。有报道称胰腺胰岛等甲状腺外组织也表达NIS。胰腺β细胞摄取放射性碘可能会潜在地损害这些细胞。在本研究中,我们讨论放射性碘与葡萄糖不耐受之间可能的关联。总体而言,胰腺摄取放射性碘可能会损害β细胞,使患者易患葡萄糖不耐受或2型糖尿病,尤其是在全甲状腺切除术后接受放射性碘治疗的患者中。需要进一步的研究来阐明和证实这种关联。